Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAINT: Trabectedin, Ipilimumab, and Nivolumab in Advanced Soft Tissue Sarcoma
NCT03138161Phase 2Recruiting
- Sponsor
- Cancer Institute Medical Group
- Start
- Apr 2017
- Primary completion
- Dec 2030
- Modality
- Monoclonal Antibodies, Nucleic Acid-Directed Small Molecules, Covalent Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trabectedin, ipilimumab, nivolumab in soft tissue sarcoma (STS), sponsored by Cancer Institute Medical Group. Started Apr 2017; status: recruiting.
02
Drugs
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT03138161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03138161.